Enter the password to continue
Incorrect password. Please try again.
The Genomic Operating System
for Employer Health Benefits
Employer health benefits decisions affecting trillions in healthcare spend are made with:
Claims data that's 18+ months old—showing what already happened, not what's coming
Models built on industry averages, not your actual population risk
Vendor promises with no way to measure true impact on outcomes
"You're managing the largest line item in your P&L with a blindfold on."
What if employers could see their population's health future—based on actual genetic risk, not speculation?
NoviHealth transforms a one-time genetic test into continuous genomic intelligence that compounds in value over time.
| Today | With NoviHealth |
|---|---|
| Historical claims | Predictive genomics |
| Reactive management | Proactive prevention |
| One-size-fits-all | Precision benefits design |
| Point-in-time testing | Continuous intelligence |
WGS fell from $1M (2007) to $200 today. Population-scale testing is finally viable.
PGS scores validated across ethnicities. Clinical actionability proven.
20%+ renewals broke the system. Benefits leaders need new tools.
Frontier models analyze genomes at scale. Compute costs declining.
30x WGS at near-cost, 10-day TAT. The test creates the data asset.
Where the value compounds—PGS scoring, PBM/EHR integration, population analytics, automated alerts on new discoveries.
Low-margin testing is customer acquisition. High-margin subscription is the business.
Cancer risk, cardiac risk, carrier status—actionable insights from day one
Know how you metabolize medications before you take them
Alerts when new variants are discovered or prescriptions conflict with your genetics
Unlimited access to certified counselors who understand your results
| Scenario | Typical Cost | With NoviHealth | Savings |
|---|---|---|---|
| Late-stage cancer | $375,000 | $45,000 | $330,000 |
| Adverse drug event (PGx) | $120,000 | Prevented | $120,000 |
| Preventable stroke (AFib) | $250,000 | Prevented | $250,000 |
Test investment: $250K one-time | Annual PMPM: $24-60K | Expected prevented events: 3-5/year
Net annual savings: $500K–$1M
| Price to employer | $250 |
| COGS (wet lab + sequencing) | $180-200 |
| Gross margin | 20-28% |
Purpose: Customer acquisition. Creates the data asset.
| PMPM price | $2-5 |
| Compute + human costs | $0.50-1.00 |
| Gross margin | 70-80% |
Purpose: Recurring revenue. Where value compounds.
| Metric | Year 1 | Year 3 | Year 5 |
|---|---|---|---|
| Tested lives | 10,000 | 200,000 | 1,000,000 |
| Testing revenue | $2.5M | $50M | $250M |
| PMPM revenue | $0.36M | $7.2M | $36M |
| Total revenue | $2.86M | $57.2M | $286M |
| Blended gross margin | 35% | 55% | 60% |
As PMPM revenue grows relative to testing, margins expand significantly.
Every genome adds to population intelligence. Can't be replicated overnight.
Connected to HRIS, pharmacy, EHR. Switching costs are enormous.
Continuous reanalysis means value increases. Leaving = losing all insights.
More employers = better PGS accuracy for everyone.
Expected retention: 95%+ once past year 1
| Capability | Genomic Life | Color Health | Helix | NoviHealth |
|---|---|---|---|---|
| Full 30x WGS | ✗ | ✗ | ✗ | ✓ |
| Continuous reanalysis | ✗ | ✗ | ✗ | ✓ |
| Population analytics | Limited | ✗ | Limited | ✓ |
| PMPM subscription model | ✗ | ✗ | ✗ | ✓ |
No competitor offers employer-sponsored continuous genomic intelligence with population-level analytics and recurring revenue model.
NoviHealth is positioned for acquisition by compute-first companies, not just traditional labs.
Quest, Labcorp, UHC, CVS
Revenue multiple
Google, Microsoft, Amazon, Oracle
Revenue multiple
Tempus, Verily, Palantir
Revenue multiple
Year 4 at $150M revenue: $600M–$1.2B
Year 6 at $400M revenue: $2.4B+
Population genomic database is irreplicable—can't be built overnight
PMPM subscription = recurring revenue model tech acquirers understand
Their existing AI/ML infrastructure can immediately amplify our analysis
Clean, enterprise-focused healthcare play—no clinical risk, no claims liability
| Deal | Acquirer | Target | Rationale |
|---|---|---|---|
| Feb 2025 | Tempus AI | Ambry Genetics | Testing + AI platform integration |
| May 2025 | GeneDx | Fabric Genomics | AI-powered interpretation |
| Q2 2025 | Illumina | SomaLogic | Multiomics expansion |
| Jan 2025 | NVIDIA | Illumina/Mayo | AI partnership for genomics |
The market is actively consolidating around genomics + AI + healthcare. NoviHealth sits at this intersection.
Building the genomic operating system that transforms employer health benefits from reactive cost management to precision population medicine.
The future of employer health benefits is genomic.
We're building the platform to deliver it.
Contact: investor@novihealth.com
Background in employer benefits, healthcare technology leadership
Clinical genomics expertise, genetic counseling background
Bioinformatics platform development, AI/ML in healthcare
Lab operations, CLIA/CAP compliance, scale operations
[Team bios to be added]